Urocortin 1 improves renal function in rats with streptozotocin-induced diabetes by inhibiting overproduction of TGF-Β1 and VEGF

British Journal of Pharmacology

Volumn 157, Issue 6, 2009, Pages 994-1003

  Li, Xuan ^a,b   Hu, Jue ^a   Zhang, Qichun ^a,b   Sun, Xiaoyu ^b   Li, Shengnan ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Diabetic nephropathy; Extracellular matrix; Transforming growth factor beta 1; Urocortin 1; Vascular endothelial growth factor

Indexed keywords

ASTRESSIN; FREUND ADJUVANT; GLUCOSE; INSULIN; MESSENGER RNA; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA; UROCORTIN I; VASCULOTROPIN;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIABETIC NEPHROPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; KIDNEY FUNCTION; KIDNEY MASS; MALE; MESANGIUM CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOCIN DIABETES;

ANIMALS; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; KIDNEY FUNCTION TESTS; MALE; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; TRANSFORMING GROWTH FACTOR BETA1; UROCORTINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70350336006     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00264.x     Document Type: Article

References (29)

1. Ahn JD, Morishita R, Kaneda Y, Kim HJ, Kim YD, Lee HJ et al. (2004). Transcription factor decoy for AP-1 reduces mesangial cell proliferation and extracellular matrix production in vitro and in vivo. Gene Ther 11: 916-923.
2. Baldamus CA, Galaske R, Eisenbach GM, Krause HP, Stolte H (1975). Glomerular protein filtration in normal and nephritic rats. A micro-puncture study. Contrib Nephrol 1: 37-49.
3. Bilous RW, Mauer SM, Sutherland DE, Steffes MW (1989). Mean glom-erular volume and rate of development of diabetic nephropathy. Diabetes 38: 1142-1147.
4. Caramori ML, Kim Y, Huang C, Fish AJ, Rich SS, Miller ME et al. (2002). Cellular basis of diabetic nephropathy: 1. Study design and renal structural-functional relationships in patients with longstanding type 1 diabetes. Diabetes 51: 506-513.
5. Cooper ME (2001). Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetolo-gia 44: 1957-1972.
6. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B et al. (1999). Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 48: 2229-2239.
7. Gruden G, Thomas S, Burt D, Zhou W, Chusney G, Gnudi L et al. (1999). Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells. J Am Soc Nephrol 10: 730-737.
8. Haneda M, Koya D, Isono M, Kikkawa R (2003). Overview of glucose signaling in mesangial cells in diabetic nephropathy. J Am Soc Nephrol 14: 1374-1382.
9. Hellmich B, Schellner M, Schatz H, Pfeiffer A (2000). Activation of transforming growth factor-beta1 in diabetic kidney disease. Metabolism 49: 353-359.
10. Huang Y, Chan FL, Lau CW, Tsang SY, He GW, Chen ZY et al. (2002). Urocortin-induced endothelium-dependent relaxation of rat coronary artery: role of nitric oxide and K+ channels. Br J Pharmacol 135: 1467-1476.
11. Ibrahim S, Rashed L (2007). Estimation of transforming growth factor-beta 1 as a marker of renal injury in type II diabetes mellitus. Saudi Med J 28: 519-523.
12. Jafar TH, Schmid CH, Levey AS (2005). Serum creatinine as maker of kidney function in south Asians: a study of reduced GFR in adults in Pakistan. J Am Soc Nephrol 16: 1413-1419.
13. Lenz O, Zheng F, Vilar J, Doublier S, Lupia E, Schwedler S et al. (1998). The inheritance of glomerulosclerosis in mice is controlled by multiple quantitative trait loci. Nephrol Dial Transplant 13: 3074-3078.
14. Li X, Hu J, Zhang R, Sun X, Zhang Q, Guan X et al. (2008). Urocortin ameliorates diabetic nephropathy in obese db/db mice. Br J Pharmacol 154: 1025-1034.
15. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC (1984). Structural-functional relationships in diabetic nephropathy. J Clin Invest 74: 1143-1155.
16. Mogensen CE, Christensen CK, Vittinghus E (1983). The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 32 (Suppl. 2): 64-78.
17. Rademaker MT, Charles CJ, Espiner EA, Frampton CM, Lainchbury JG, Richards AM (2005). Four-day urocortin-I administration has sustained beneficial haemodynamic, hormonal, and renal effects in experimental heart failure. Eur Heart J 26: 2055-2062.
18. Rahn KH, Heidenreich S, Brückner D (1999). How to assess glomerular function and damage in humans. J Hypertens 17: 309-317.
19. Russo LM, del Re E, Brown D, Lin HY (2007). Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of post-glomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor. Diabetes 56: 380-388.
20. Senger DR, Galli SJ, Dvorak AM (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985.
21. Sun SZ, Wang Y, Li Q, Tian YJ, Liu MH, Yu YH (2006). Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats. Chin Med J (Engl) 119: 814-821.
22. Sung SH, Ziyadeh FN, Wang A, Pyagay PE, Kanwar YS, Chen S (2006). Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J Am Soc Nephrol 17: 3093-3104.
23. De Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH (2001). Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 12: 993-1000.
24. Wang J, Xu Y, Xu Y, Zhu H, Zhang R, Zhang G et al. (2008). Urocor-tin's inhibition of tumor growth and angiogenesis in hepatocellular carcinoma via corticotrophin-releasing factor receptor 2. Cancer Invest 26: 359-368.
25. Wang L, Kwak JH, Kim SI, He Y, Choi ME (2004). Transforming growth factor-beta1 stimulates vascular endothelial growth factor 164 via mitogen-activated protein kinase kinase 3-p38alpha and p38delta mitogen-activated protein kinase-dependent pathway in murine mesangial cells. J Biol Chem 279: 33213-33219.
26. Wolf G, Chen S, Ziyadeh FN (2005). From the periphery of the glom-erular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 54: 1626-1634.
27. de Zeeuw D (2007). Albuminuria: a target for treatment of type 2 diabetic nephropathy. Semin Nephrol 27: 172-181.
28. Ziyadeh FN, Wolf G (2008). Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev 4: 39-45.
29. Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW, Isono M et al. (2000). Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97: 8015-8020.